NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
Clinical Trials
10 trialsNCT06870760 2026-01-21
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
Recruiting
NCT03820817 2025-04-20
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
Phase 1 Active not recruiting
NCT06644443 2024-10-16
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT05362331 2023-02-09
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
Phase NA Withdrawn
NCT02556931 2022-11-03
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00048412 2020-01-18
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
Phase 1/2 Completed
NCT01002755 2019-05-07
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00579111 2016-05-04
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Phase 1/2 Terminated
NCT01755000 2013-09-02
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
Washington University School of Medicine
Phase NA Completed